Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
77.30
+6.10 (8.57%)
Apr 28, 2026, 1:30 PM CST
-8.09%
Market Cap 9.48B
Revenue (ttm) 36.45M
Net Income (ttm) -114.13M
Shares Out 122.62M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,265,520
Average Volume 316,825
Open 71.20
Previous Close 71.20
Day's Range 68.90 - 78.20
52-Week Range 58.30 - 118.00
Beta 0.15
RSI 65.91
Earnings Date May 12, 2026

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 6617
Full Company Profile

Financial Performance

In 2025, Gongwin Biopharm Holdings's revenue was 36.45 million, an increase of 13.75% compared to the previous year's 32.04 million. Losses were -114.13 million, 38.3% more than in 2024.

Financial Statements

News

There is no news available yet.